Giorgio Maria Saracco

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/148439/giorgio-maria-saracco-publications-by-year.pdf

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

185
papers5,005
citations35
h-index66
g-index206
ext. papers6,039
ext. citations4.6
avg, IF5.07
L-index

#	Paper	IF	Citations
185	Effect of COVID-19 Pandemic on Hepatocellular Carcinoma Diagnosis: Results from a Tertiary Care Center in North-West Italy <i>Current Oncology</i> , 2022 , 29, 1422-1429	2.8	O
184	Autoimmune hepatitis or Drug-induced autoimmune hepatitis following Covid- 19 vaccination?. <i>Liver International</i> , 2022 ,	7.9	1
183	Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C successfully treated with direct-acting antiviral agents. <i>Liver International</i> , 2021 , 41, 276-287	7.9	6
182	Transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome - chronic kidney disease: Impact on renal function. <i>Digestive and Liver Disease</i> , 2021 ,	3.3	2
181	Management of Dyspepsia and Gastroparesis in Patients with Diabetes. A Clinical Point of View in the Year 2021. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
180	Inflammatory Bowel Disease Nurse-Practical Messages Nursing Reports, 2021, 11, 229-241	0.8	О
179	The impact of direct-acting antiviral treatment on glycemic homeostasis in patients with chronic hepatitis C. <i>Minerva Gastroenterology</i> , 2021 , 67, 264-272	3	2
178	Elastography for characterization of focal liver lesions: current evidence and future perspectives. <i>Minerva Gastroenterology</i> , 2021 , 67,	3	2
177	Long-term benefits of viral clearance on extrahepatic manifestations of hepatitis C virus infection: the light at the end of the tunnel?. <i>Minerva Gastroenterology</i> , 2021 , 67, 215-217	3	1
176	Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancers</i> , 2021 , 13,	6.6	9
175	A Retrospective Experience of Histology in a Large Sample of Subjects in Northern Italy. <i>Life</i> , 2021 , 11,	3	1
174	Peripheral neuropathy after viral eradication with direct-acting antivirals in chronic HCV hepatitis: A prospective study. <i>Liver International</i> , 2021 , 41, 2611-2621	7.9	1
173	Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn B Disease: A Prospective Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
172	Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C. <i>Liver International</i> , 2021 , 41, 640	7.9	1
171	An unpleasant souvenir: Endoscopic finding of Trichuris trichiura (Nematoda: Trichuridae). <i>Parasitology International</i> , 2021 , 80, 102220	2.1	1
170	Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study. <i>Digestive and Liver Disease</i> , 2021 , 53, 712-716	3.3	2
169	Higher Efficiency of Percutaneous Microwave (MWA) Than Radiofrequency Ablation (RFA) in Achieving Complete Response in Cirrhotic Patients with Early Hepatocellular Carcinoma. <i>Current Oncology</i> , 2021 , 28, 1034-1044	2.8	5

(2020-2021)

168	The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. <i>Biology</i> , 2021 , 10,	4.9	2
167	Helicobacter pylori eradication with a clarithromycin-based triple therapy in elderly patients. <i>Panminerva Medica</i> , 2021 , 63, 332-335	2	1
166	Recent advances in the treatment of irritable bowel syndrome. <i>Polish Archives of Internal Medicine</i> , 2021 , 131, 709-715	1.9	2
165	and Respiratory Diseases: 2021 Update. <i>Microorganisms</i> , 2021 , 9,	4.9	4
164	The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease. <i>Journal of Advanced Research</i> , 2021 , 33, 183-187	13	O
163	Elastography for characterization of focal liver lesions: current evidence and future perspectives. <i>Minerva Gastroenterology</i> , 2021 , 67, 196-208	3	1
162	Irritable bowel syndrome and lactose intolerance: a challenging overlap. <i>Minerva Gastroenterology</i> , 2021 , 67, 67-68	3	
161	The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	10
160	Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. <i>Cancers</i> , 2020 , 12,	6.6	7
159	Pancreatic Diseases and Microbiota: A Literature Review and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
158	Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	7
157	Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity. <i>Medicines (Basel, Switzerland)</i> , 2020 , 7,	4.1	8
156	On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	16
155	Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis. <i>Medicina (Lithuania)</i> , 2020 , 56,	3.1	3
154	The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	9
153	Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020 , 96, 114985	2.9	7
152	Vedolizumab for treatment of chronic refractory pouchitis: a systematic review with pool analysis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020 , 112, 59-63	0.9	5
151	Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohnß disease: an observational study. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020 , 112, 195-200	0.9	12

150	Proctitis: a glance beyond inflammatory bowel diseases. <i>Minerva Gastroenterologica E Dietologica</i> , 2020 , 66, 252-266	1.6	1
149	Eosinophilic colitis: clinical review and 2020 update. <i>Minerva Gastroenterologica E Dietologica</i> , 2020 , 66, 157-163	1.6	3
148	Predictors of risk of fracture in inflammatory bowel diseases: a prospective study using FRAX score. <i>Minerva Gastroenterologica E Dietologica</i> , 2020 , 66, 106-112	1.6	1
147	The small intestine: barrier, permeability and microbiota. Key messages for clinicians. <i>Minerva Gastroenterologica E Dietologica</i> , 2020 ,	1.6	1
146	Risk of drug interactions and prescription appropriateness in elderly patients. <i>Irish Journal of Medical Science</i> , 2020 , 189, 953-959	1.9	7
145	Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	6
144	Differential diagnosis of pancreatic cysts: A prospective study on the role of intra-cystic glucose concentration. <i>Digestive and Liver Disease</i> , 2020 , 52, 1026-1032	3.3	7
143	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020 , 73, 842-854	13.4	108
142	Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	11
141	Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with ES1 for 8 or 12 Weeks: A Preliminary Report. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	6
140	Endoscopic Ultrasound-Guided Treatments for Non-Variceal Upper GI Bleeding: A Review of the Literature. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	5
139	Management of functional dyspepsia in 2020: a clinical point of view. <i>Minerva Gastroenterologica E Dietologica</i> , 2020 , 66, 331-342	1.6	8
138	Gastro-esophageal reflux disease: Key messages for clinicians. <i>Minerva Gastroenterologica E Dietologica</i> , 2020 ,	1.6	1
137	Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis. <i>World Journal of Hepatology</i> , 2019 , 11, 489-512	3.4	19
136	Risk factors of suspected spondyloarthritis among inflammatory bowel disease patients. <i>Scandinavian Journal of Gastroenterology</i> , 2019 , 54, 1233-1236	2.4	3
135	Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis. <i>Scandinavian Journal of Gastroenterology</i> , 2019 , 54, 407-413	2.4	20
134	Rifabutin-Based Rescue Therapy for Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	30
133	Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients. <i>Medicina (Lithuania)</i> , 2019 , 55,	3.1	7

(2018-2019)

132	Narrow-Band Imaging for Detection of Neoplasia at Colonoscopy: A Meta-analysis of Data From Individual Patients in Randomized Controlled Trials. <i>Gastroenterology</i> , 2019 , 157, 462-471	13.3	62
131	Adalimumab Therapy Improves Intestinal Dysbiosis in Crohnß Disease. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	32
130	Adalimumab versus azathioprine to halt the progression of bowel damage in Crohnß disease: application of Lihann Index. <i>Scandinavian Journal of Gastroenterology</i> , 2019 , 54, 1339-1345	2.4	3
129	Serum zonulin in patients with inflammatory bowel disease: a pilot study. <i>Minerva Medica</i> , 2019 , 110, 95-100	2.2	35
128	Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study. <i>Minerva Medica</i> , 2019 , 110, 401-409	2.2	9
127	Dupilumab to target interleukin 4 for inflammatory bowel disease? Hypothesis based on a translational message. <i>Minerva Biotecnologica</i> , 2019 , 31,	2.5	4
126	Long-term results of chronic hepatitis B antiviral treatment with nucleos(t)ide analogues: a single center experience. <i>Minerva Gastroenterologica E Dietologica</i> , 2019 , 65, 77-78	1.6	2
125	Apparent diffusion coefficient and enhancement patterns in MR imaging as markers of severe or moderate ileum inflammation in Crohnß disease. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019 , 111, 28-33	0.9	2
124	Liver stiffness-based model for portal hypertension and hepatocellular cancer risk in HBV responsive to antivirals. <i>Minerva Gastroenterologica E Dietologica</i> , 2019 , 65, 11-19	1.6	4
123	The role of topical therapy for perianal fistulizing Crohnß disease: are we forgetting something?. <i>Minerva Gastroenterologica E Dietologica</i> , 2019 , 65, 130-135	1.6	Ο
122	Wait-and-See Policy for a Small Pancreatic Schwannoma Diagnosed With Endoscopic Ultrasound With Fine-Needle Aspiration. <i>ACG Case Reports Journal</i> , 2019 , 6, e00139	0.6	3
121	HLA-DQ Genotyping, Duodenal Histology, and Response to Exclusion Diet in Autistic Children With Gastrointestinal Symptoms. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2019 , 69, 39-44	2.8	6
120	Quantitation of anti-HBe antibodies in anti-HBc-positive liver donors. <i>Journal of Hepatology</i> , 2019 , 70, 793-795	13.4	2
119	Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis. <i>Scandinavian Journal of Gastroenterology</i> , 2018 , 53, 734-740	2.4	21
118	Awareness of mutational artefacts in suboptimal DNA samples: possible risk for therapeutic choices. <i>Expert Review of Molecular Diagnostics</i> , 2018 , 18, 467-475	3.8	3
117	Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection. <i>Journal of Hepatology</i> , 2018 , 69, 301-307	13.4	69
116	Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. <i>Journal of Medical Virology</i> , 2018 , 90, 320-327	19.7	57
115	Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. <i>Liver International</i> , 2018 , 38, 715-723	7.9	15

114	Fecal calprotectin: beyond intestinal organic diseases. <i>Panminerva Medica</i> , 2018 , 60, 29-34	2	24
113	Basic and clinical aspects of resistin. <i>Minerva Biotecnologica</i> , 2018 , 30,	2.5	2
112	Is there a link between periampullary diverticula and biliopancreatic disease? An EUS approach to answer the question. <i>Digestive and Liver Disease</i> , 2018 , 50, 925-930	3.3	2
111	Pediatric epilepsy and psychiatric comorbidity: could celiac disease diagnosis improve the outcome?. <i>Minerva Pediatrica</i> , 2018 , 70, 634-635	1.6	O
110	The role of microbiota in autism spectrum disorders. <i>Minerva Gastroenterologica E Dietologica</i> , 2018 , 64, 333-350	1.6	20
109	Hepatitis B Core-Related Antigen: A Serum Biomarker for Intrahepatic Covalently-Closed-Circular DNA. <i>Clinical Laboratory</i> , 2018 , 64, 411-412	2	6
108	A rare case of gastric fistulization of a main-duct intraductal papillary mucinous neoplasm. <i>Minerva Gastroenterologica E Dietologica</i> , 2018 , 64, 383-385	1.6	1
107	The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets. <i>Scandinavian Journal of Gastroenterology</i> , 2018 , 53, 141-146	2.4	11
106	Helicobacter pylori and proton pump inhibitor therapy: One diagnostic method is enough?. <i>European Journal of Internal Medicine</i> , 2018 , 50, e29-e30	3.9	
105	Prevalence of Micronutrient Deficiency in Patients with Morbid Obesity Before Bariatric Surgery: What About Celiac Disease?. <i>Obesity Surgery</i> , 2018 , 28, 550-551	3.7	4
104	Adalimumab trough levels predict Crohn disease clinical course. <i>Digestive and Liver Disease</i> , 2018 , 50, 204-206	3.3	3
103	Gastroenterology today: between certainties and news. <i>Minerva Gastroenterologica E Dietologica</i> , 2018 , 64, 323-332	1.6	9
102	Irritable bowel syndrome: the clinical approach. <i>Panminerva Medica</i> , 2018 , 60, 213-222	2	32
101	Pharmacological considerations and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018. <i>Minerva Gastroenterologica E Dietologica</i> , 2018 , 64, 310-321	1.6	28
100	Management of Pt1 tumours removed by endoscopy during colorectal cancer screening: Outcome and treatment quality indicators. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 1873-1879	3.6	8
99	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , 2018 , 391, 2417-2429	40	176
98	Evaluation of Clensia, a new low-volume PEG bowel preparation in colonoscopy: Multicentre randomized controlled trial versus 4L PEG. <i>Digestive and Liver Disease</i> , 2017 , 49, 651-656	3.3	12
97	Negativization of viremia prior to liver transplant reduces early allograft dysfunction in hepatitis C-positive recipients. <i>Liver Transplantation</i> , 2017 , 23, 915-924	4.5	8

96	Favorable short-term outcome of hepatitis C virus-positive liver graft with bridging fibrosis: A plea for very early viral eradication. <i>Hepatology</i> , 2017 , 65, 2116-2118	11.2	7
95	Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. <i>American Journal of Hematology</i> , 2017 , 92, 1349-1355	7.1	33
94	Comment on "Advanced Hepatic Fibrosis in Fatty Liver Disease Linked to Hyperplastic Colonic Polyp". <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2017 , 2017, 4083272	2.8	О
93	Liver fibrosis: the 2017 state of art. <i>Panminerva Medica</i> , 2017 , 59, 320-331	2	35
92	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 427-434	18.8	13
91	Efficacy of infliximab biosimilars in patients with Crohnß disease. <i>Lancet, The</i> , 2017 , 390, 2435-2436	40	5
90	Comments on Sulimani et al.: A weekly 35,0001U vitamin D supplementation improves bone turnover markers in vitamin D deficient Saudi adolescent females. <i>Archives of Osteoporosis</i> , 2017 , 12, 102	2.9	1
89	Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-∃ <i>Hepatology Research</i> , 2017 , 47, 747-754	5.1	17
88	Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis. <i>Liver International</i> , 2017 , 37, 62-70	7.9	27
87	Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a "real world" study by 13C-octanoic Acid Breath Test. <i>Minerva Medica</i> , 2017 , 108, 489-495	2.2	11
86	Non-organ-specific autoimmunity in patients suffering from gastric ulcer with and without Helicobacter pylori infection. <i>Minerva Biotechnology and Biomolecular Research</i> , 2017 , 29,		6
85	Finally, it is bismuthß time. Saudi Journal of Gastroenterology, 2017, 23, 127	3	
84	Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II. <i>Panminerva Medica</i> , 2017 , 59, 283-289	2	26
83	Endoscopic ultrasound to diagnose pneumatosis cystoides intestinalis (with video). <i>Endoscopic Ultrasound</i> , 2017 , 6, 416-417	3.6	4
82	Amoxycillin and Metronidazole Therapy for Helicobacter pylori Eradication: A 10-Year Trend in Turin, Italy. <i>Balkan Medical Journal</i> , 2017 , 34, 290-291	1.5	5
81	The first-line treatment of Helicobacter pylori infection in Piedmont in the year 2017. <i>Panminerva Medica</i> , 2017 , 59, 199	2	1
80	Food supplements, stress and gastrointestinal diseases. <i>Panminerva Medica</i> , 2017 , 59, 274-275	2	
79	Comment on Helicobacter pylori seroprevalence and the occurrence and severity of psoriasis. <i>Anais Brasileiros De Dermatologia</i> , 2017 , 92, 584	1.6	Ο

78	Stereotactic ablative radiotherapy in the treatment of hepatocellular carcinoma >3′cm. <i>Medical Oncology</i> , 2016 , 33, 104	3.7	4
77	Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality?. <i>Digestive and Liver Disease</i> , 2016 , 48, 105-11	3.3	42
76	Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?. <i>Digestive and Liver Disease</i> , 2016 , 48, 650-5	3.3	6
75	Etiology of chronic liver diseases in the Northwest of Italy, 1998 through 2014. <i>World Journal of Gastroenterology</i> , 2016 , 22, 8187-93	5.6	27
74	Response to: Comment on "Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients". <i>Gastroenterology Research and Practice</i> , 2016 , 2016, 4760378	2	
73	Reply to "Chronic hepatitis C and diabetes: More questions than answers with the new direct acting antiviral drugs?". <i>Digestive and Liver Disease</i> , 2016 , 48, 1101-2	3.3	
72	On elevated alanine aminotransferase in type 1 diabetes mellitus. <i>Minerva Gastroenterologica E Dietologica</i> , 2016 , 62, 223	1.6	1
71	Helicobacter pylori infection and ischemic heart disease: could experimental data lead to clinical studies?. <i>Minerva Cardioangiologica</i> , 2016 , 64, 686-96	1.1	17
70	A 2016 panorama of Helicobacter pylori infection: key messages for clinicians. <i>Panminerva Medica</i> , 2016 , 58, 304-317	2	98
69	Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study. <i>Digestive and Liver Disease</i> , 2015 , 47, 405-	1 0 3	6
68	Prospective randomized trial: endoscopic follow up 3 vs 6 months after esophageal variceal eradication by band ligation in cirrhosis. <i>European Journal of Internal Medicine</i> , 2014 , 25, 674-9	3.9	5
67	Narrow band imaging vs. high definition colonoscopy for detection of colorectal adenomas in patients with positive faecal occult blood test: a randomised trial. <i>Digestive and Liver Disease</i> , 2014 , 46, 803-7	3.3	11
66	Durability of the response to peginterferon-2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting. <i>European Journal of Gastroenterology and Hepatology</i> , 2014 , 26, 52-8	2.2	2
65	Type 2 diabetes mellitus and chronic hepatitis C: which is worse? Results of a long-term retrospective cohort study. <i>Digestive and Liver Disease</i> , 2012 , 44, 406-12	3.3	13
64	Safety of propofol in cirrhotic patients undergoing colonoscopy and endoscopic retrograde cholangiography: results of a prospective controlled study. <i>European Journal of Gastroenterology and Hepatology</i> , 2012 , 24, 70-6	2.2	21
63	Progressive increase of matrix metalloprotease-9 and interleukin-8 serum levels during carcinogenic process in human colorectal tract. <i>PLoS ONE</i> , 2012 , 7, e41839	3.7	24
62	Transcatheter arterial chemoembolization for hepatocellular carcinoma in cirrhosis: influence on portal hypertension. <i>European Journal of Gastroenterology and Hepatology</i> , 2011 , 23, 573-7	2.2	9
61	The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. <i>Hepatology</i> , 2011 , 54, 1208-16	11.2	323

(2003-2011)

60	transplant biliary complications: results of a cohort study with long-term follow-up. <i>Gut and Liver</i> , 2011 , 5, 328-34	4.8	33
59	Response to Yeh. American Journal of Gastroenterology, 2009 , 104, 1052-1052	0.7	
58	Helicobacters and extragastric diseases. <i>Helicobacter</i> , 2009 , 14 Suppl 1, 58-68	4.9	56
57	Preliminary experience with a new cytology brush in EUS-guided FNA. <i>Gastrointestinal Endoscopy</i> , 2009 , 70, 1220-4	5.2	39
56	The natural history of gastrointestinal subepithelial tumors arising from muscularis propria: an endoscopic ultrasound survey. <i>Journal of Clinical Gastroenterology</i> , 2009 , 43, 821-5	3	21
55	High-normal blood pressure is associated with a cluster of cardiovascular and metabolic risk factors: a population-based study. <i>Journal of Hypertension</i> , 2009 , 27, 102-8	1.9	23
54	Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1966-72	0.7	15
53	Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. <i>American Journal of Gastroenterology</i> , 2008 , 103, 2481-7	0.7	83
52	Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection?. <i>Journal of Medical Virology</i> , 2008 , 80, 628-31	19.7	11
51	Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. <i>Gastroenterology</i> , 2007 , 132, 2304-12	13.3	204
50	Fatal multiple systemic embolisms after injection of cyanoacrylate in bleeding gastric varices of a patient who was noncirrhotic but with idiopathic portal hypertension. <i>Gastrointestinal Endoscopy</i> , 2007 , 65, 345-7	5.2	45
49	AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. <i>Journal of Hepatology</i> , 2007 , 46, 1026-33	13.4	63
48	Long-term follow-up of previous hepatitis C virus positive nonresponders to interferon monotherapy successfully retreated with combination therapy: are they really cured?. <i>American Journal of Gastroenterology</i> , 2006 , 101, 1811-6	0.7	22
47	Digestive endoscopy is not a major risk factor for transmitting hepatitis C virus. <i>Annals of Internal Medicine</i> , 2005 , 142, 903-9	8	48
46	Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 347-57	9.7	159
45	Prevalence of non-organ-specific autoantibodies in patients suffering from duodenal ulcer with and without Helicobacter pylori infection. <i>Digestive Diseases and Sciences</i> , 2004 , 49, 395-8	4	13
44	Temporary placement of an expandable polyester silicone-covered stent for treatment of refractory benign esophageal strictures. <i>Gastrointestinal Endoscopy</i> , 2004 , 60, 513-9	5.2	203
43	Effects of long-term Irbesartan in reducing portal pressure in cirrhotic patients: comparison with propranolol in a randomised controlled study. <i>Journal of Hepatology</i> , 2003 , 38, 455-60	13.4	21

42	Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension. <i>Digestive Diseases and Sciences</i> , 2002 , 47, 401-4	4	19
41	A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. <i>Hepatology</i> , 2002 , 36, 959-66	11.2	22
40	Spectral electroencephalogram analysis in hepatic encephalopathy and liver transplantation. <i>Liver Transplantation</i> , 2002 , 8, 630-5	4.5	27
39	Successful closure of a postsurgical benign esophagomediastinal fistula by temporary placement of a polyester, expandable stent: Case report and review. <i>Gastrointestinal Endoscopy</i> , 2002 , 56, 747-750	5.2	19
38	A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. <i>Hepatology</i> , 2002 , 36, 959-966	5 ^{11.2}	
37	A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. <i>Hepatology</i> , 2001 , 34, 133-8	11.2	44
36	Comparison of complication rates between endoscopic and fluoroscopic percutaneous gastrostomies. <i>Nutrition</i> , 2001 , 17, 967-8	4.8	9
35	Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group. <i>European Journal of Gastroenterology and Hepatology</i> , 2001 , 13, 149-55	2.2	4
34	Self-expanding covered esophageal ultraflex stent for palliation of malignant colorectal anastomotic obstruction complicated by multiple fistulas. <i>Gastrointestinal Endoscopy</i> , 2000 , 51, 346-8	5.2	25
33	Covered metal stents for management of inoperable malignant colorectal strictures. <i>Gastrointestinal Endoscopy</i> , 2000 , 52, 735-40	5.2	106
32	Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. <i>American Journal of Gastroenterology</i> , 1999 , 94, 2246-50	0.7	59
31	Changing pattern of chronic hepatitis D in Southern Europe. <i>Gastroenterology</i> , 1999 , 117, 161-6	13.3	97
30	Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial. <i>Hepatology</i> , 1998 , 28, 341-6	11.2	50
29	A practical guide to the use of interferons in the management of hepatitis virus infections. <i>Drugs</i> , 1997 , 53, 74-85	12.1	23
28	Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial. <i>Journal of Hepatology</i> , 1997 , 27, 56-6	5 2 3.4	41
27	HCV genotypes in patients with liver disease of different stages and severity. <i>Journal of Hepatology</i> , 1997 , 26, 1173-8	13.4	42
26	Predictors of response to interferon therapy. <i>Digestive Diseases and Sciences</i> , 1996 , 41, 115S-120S	4	17

(1991-1995)

24	Primary liver cancer is of multifactorial origin: importance of hepatitis B virus infection and dietary aflatoxin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1995 , 10, 604-8	4	11
23	The long-term efficacy of interferon alfa in chronic hepatitis C patients: a critical review. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1995 , 10, 668-73	4	15
22	Human immunodeficiency virus infection as risk factor for mother-to-child hepatitis C virus transmission; Persistence of antiliepatitis C virus in children is associated with the mother antiliepatitis C virus immunoblotting pattern. <i>Hepatology</i> , 1995 , 21, 328-332	11.2	67
21	Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. <i>Hepatology</i> , 1995 , 22, 1374-1378	11.2	58
20	Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes 1995 , 22, 1374		15
19	Long-term response to interferon-alfa 2b re-treatment in chronic hepatitis C. <i>Journal of Hepatology</i> , 1994 , 21, 278-9	13.4	5
18	Interferon in chronic hepatitis B. <i>Antiviral Research</i> , 1994 , 24, 137-43	10.8	5
17	Detection of hepatitis C virus RNA by reverse-transcriptase and polymerase chain reaction: clinical applications of quantitative analysis. <i>Clinical and Diagnostic Virology</i> , 1994 , 1, 289-97		12
16	Wild-type and HBeAg-minus HBV Fluctuations: Cause or Effect of Chronic Hepatitis B Pathogenic Mechanisms? 1994 , 261-264		
15	Clinical significance of the antibody to the putative core protein of hepatitis C virus in patients with chronic liver disease. <i>Liver</i> , 1993 , 13, 222-6		3
14	Hepatitis C virus infection and disease. Diagnostic problems. <i>Journal of Hepatology</i> , 1993 , 17 Suppl 3, S78-82	13.4	11
13	Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. <i>Gastroenterology</i> , 1993 , 105, 845-50	13.3	169
12	Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-2b. <i>Hepatology</i> , 1993 , 18, 1300-1305	11.2	144
11	Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-2b 1993 , 18, 1300		13
10	Histologic changes in liver biopsy specimens produced by recombinant interferon alpha-2b therapy for chronic non-A,non-B viral hepatitis. A randomized controlled trial. <i>American Journal of Clinical Pathology</i> , 1992 , 98, 397-401	1.9	21
9	Hepatitis B x antigen and polymerase antibodies in the serum of hepatitis B carriers with or without hepatitis delta virus infection. Effects of interferon treatment. <i>Journal of Hepatology</i> , 1992 , 14, 286-93	13.4	4
8	Chronic active hepatitis B. Interferon-activated natural killer-like cells against a hepatoma cell line transfected with the hepatitis B virus nucleic acid. <i>Liver</i> , 1991 , 11, 106-13		8
7	Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. <i>Virology</i> , 1991 , 180, 842-8	3.6	537

6	Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D. <i>Hepatology</i> , 1991 , 13, 413-416	11.2	78
5	Sequence variation in hepatitis C viral isolates. <i>Journal of Hepatology</i> , 1991 , 13 Suppl 4, S6-14	13.4	42
4	Interferon treatment and ALT normalization concomitant with ongoing viral replication. <i>Hepatology</i> , 1990 , 12, 790-1	11.2	
3	A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy. <i>Hepatology</i> , 1989 , 10, 336-41	11.2	90
2		11.2	90